Mark Pegram, MD, Discusses the HER2CLIMB Trial and the Promising Nature of Tucatinib Therapy

from Oncology Learning Network · host HMP Global

Dr Pegram, Associate Director for Clinical Research, Stanford Comprehensive Cancer Institute, Palo Alto, California, spoke with Oncology Learning Network about the basis, findings, and clinical significance of the HER2CLIMB clinical trial examining the use of tucatinib therapy in patients with HER2-positive breast cancer.

Episode metadata supplied by the publisher feed · Published Jan 10, 2020

Embed this episode

Attribution link and audio player

Ready to play

Mark Pegram, MD, Discusses the HER2CLIMB Trial and the Promising Nature of Tucatinib Therapy

0:00 16:58

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Oncology Learning Network?

This episode is 16 minutes long.

When was this Oncology Learning Network episode published?

This episode was published on January 10, 2020.

Can I download this Oncology Learning Network episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!